34 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
39
Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.
The University of Kansas
11
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.
Shandong University
72
Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Sloan-Kettering Institute For Cancer Research
40
Identification of novel HSP90a/ß isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as Huntington's disease.
Vertex Pharmaceuticals
6
Correlation between chemotype-dependent binding conformations of HSP90a/ß and isoform selectivity-Implications for the structure-based design of HSP90a/ß selective inhibitors for treating neurodegenerative diseases.
Vertex Pharmaceuticals
13
Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.
Memorial Sloan-Kettering Cancer Center
12
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Infinity Pharmaceuticals
71
Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.
Dezhou University
18
Investigation of the site 2 pocket of Grp94 with KUNG65 benzamide derivatives.
The University of Notre Dame
2
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
28
Elucidation of novel TRAP1-Selective inhibitors that regulate mitochondrial processes.
University of Notre Dame
20
Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects.
Sichuan University
36
Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships.
Jiangxi Science & Technology Normal University
15
Synthesis and Validation of the First Cell-Impermeable Hsp90α-Selective Inhibitors.
The University of Notre Dame
42
Structure-Activity Relationship Study of Tertiary Alcohol Hsp90α-Selective Inhibitors with Novel Binding Mode.
The University of Notre Dame
25
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.
National Institute of Diabetes & Digestive & Kidney Diseases
8
Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.
Shandong University
39
Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects.
China Pharmaceutical University
4
Thermodynamic Dissection of Potency and Selectivity of Cytosolic Hsp90 Inhibitors.
Taiho Pharmaceutical
31
Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity.
Ewha Womans University
22
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with
The University of Notre Dame
49
Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
China Pharmaceutical University
39
Biological Evaluation of 5'-(
National Institute of Diabetes and Digestive and Kidney Diseases
32
Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.
Daegu-Gyeongbuk Medical Innovation Foundation (Dgmif)
8
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
China Pharmaceutical University
9
Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.
China Pharmaceutical University
3
Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.
Hauptman-Woodward Medical Research Institute
282
COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF
Gluetacs Therapeutics (Shanghai)